Capital Impact Advisors’s Editas Medicine EDIT Stock Holding History

Capital Impact Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,537	Closed	-$572K	–	192
2021 Q4	$572K	Sell	21,537 -2,224	-9%	-$76.5K	0.39%	78
2021 Q3	$976K	Sell	23,761 -7,719	-25%	-$423K	0.39%	101
2021 Q2	$1.78M	Buy	31,480 +22,515	+251%	+$832K	0.58%	76
2021 Q1	$377K	Sell	8,965 -121,035	-93%	-$6.9M	0.13%	101
2020 Q4	$9.11M	Buy	130,000 +105,000	+420%	+$4.31M	2.24%	6
2020 Q3	$702K	Buy	+25,000	New	+$814K	0.21%	105
2019 Q2	–	Sell	-63,637	Closed	-$1.32M	–	128
2019 Q1	$1.32M	Hold	63,637	–	–	0.58%	100
2018 Q4	$1.32M	Buy	63,637 +6,231	+11%	+$170K	0.56%	103
2018 Q3	$1.86M	Buy	57,406 +10,138	+21%	+$328K	0.64%	77
2018 Q2	$1.7M	Buy	47,268 +6,170	+15%	+$218K	0.63%	92
2018 Q1	$1.36M	Buy	+41,098	New	+$1.46M	0.56%	94

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital Impact Advisors's EDIT Position: Q1 2022 in Review

Capital Impact Advisors sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 21,537 shares — an estimated $572K sold.

Capital Impact Advisors first reported a position in EDIT in Q1 2018 and held it in 11 quarters. The position peaked at $9.11M in Q4 2020. 257 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

Capital Impact Advisors reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
Capital Impact Advisors sold 21,537 Editas Medicine shares in Q1 2022, an estimated $572K.
Capital Impact Advisors first reported a position in Editas Medicine in Q1 2018 and held it in 11 quarters.
Capital Impact Advisors's Editas Medicine position peaked at $9.11M in Q4 2020.
257 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Capital Impact Advisors's 13F filing for Q1 2022, filed 16 May 2022.